Get started
Author

Peijie Hou

Observed names: Hou, Peijie, P Hou, P. Hou, PEIJIE HOU
ORCID: 0000-0003-4899-7391
Observed ORCID: 0000-0003-4899-7391
OpenAlex ID: A5060656642
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
2024 · Jeffrey S Weber, Matteo S Carlino, et al. · The Lancet · 902
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
2021 · Meagan P. O’Brien, Eduardo Forleo-Neto, et al. · New England Journal of Medicine · 448
PDF
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al. · Cancer Discovery · 121
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
2023 · Maja Di Rocco, Eduardo Forleo-Neto, et al. · Nature Medicine · 60
PDF
Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial
2023 · Adnan Khattak, Matteo Carlino, et al. · Cancer Research · 51
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
2022 · Gary A Herman, Meagan P O'Brien, et al. · The Lancet Infectious Diseases · 41
PDF
Hierarchical Group Testing for Multiple Infections
2016 · Peijie Hou, Joshua M. Tebbs, et al. · Biometrics · 25
Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
2020 · Huamao M. Lin, Xiaoyun Pan, et al. · Journal of Medical Economics · 21
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
2019 · Robert M. Rifkin, Jill A. Bell, et al. · PharmacoEconomics - Open · 19
PDF
Array testing for multiplex assays
2018 · Peijie Hou, Joshua M Tebbs, et al. · Biostatistics · 16
Real-World Treatment Duration in ALK-Positive Non-Small-Cell Lung Cancer Patients Receiving Brigatinib Through the Early Access Program
2020 · Huamao M Lin, Xiaoyun Pan, et al. · Future Oncology · 11
PDF
Partitioning of $$\alpha $$ α and $$\beta $$ β diversity using hierarchical Bayesian modeling of species distribution and abundance
2014 · Jing Zhang, Thomas O. Crist, et al. · Environmental and Ecological Statistics · 8
Abstract CT141: mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro) in advanced unresectable HPV- head & neck carcinoma (HNSCC): Clinical & translational analysis
2024 · Julie E. Bauman, Ricklie A. Julian, et al. · Cancer Research · 7
Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)
2019 · M.M. Lin, X. Pan, et al. · Annals of Oncology · 7
Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
2023 · Maja Di Rocco, Eduardo Forleo-Neto, et al. · medRxiv · 5
PDF
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection
2023 · Meng Xu, Meagan P O’Brien, et al. · Open Forum Infectious Diseases · 4
PDF
1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab
2023 · Justin F Gainor, Manish R Patel, et al. · 3
PDF
Garetosmab Reduces Flare-ups in Patients With Fibrodysplasia Ossificans Progressiva
2021 · Kathryn McCrystal Dahir, Jennifer Mcginniss, et al. · Journal of the Endocrine Society · 3
PDF
Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States
2019 · X. Pan, M.M. Lin, et al. · Annals of Oncology · 3
Supplementary Table 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al. · 1
Supplementary methods from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024 · Justin F. Gainor, Manish R. Patel, et al. · 1
A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2
2023 · Elizabeth R Brown, Meagan P O’Brien, et al. · Open Forum Infectious Diseases · 1
PDF
COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: Subgroup analysis in participants with cardiovascular disease and diabetes
2021 · Meagan P. O'Brien, Eduardo Forleo-Neto, et al. · American Heart Journal · 1
Pcn308 Real-world Utilization of Brigatinib in Patients With Non–small Cell Lung Cancer (nsclc)
2019 · H.M. Lin, X. Pan, et al. · Value in Health · 1
Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies
2018 · Bin Li, Kaili Ren, et al. · Blood · 1
Works count: 56
Citation count: 1,759
H-index: 11
I10-index: 11
Year
Topic
Type